GlassScriptPhysician profile
Heidi Biringer
NPI 1003832205
$5,289.68
in general payments reported to CMS, 2019-2025
34 companies · $1,521 in 2025
The $1,521 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $807 · 2023: $1,454 · 2024: $1,508 · 2025: $1,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,403 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,402.77 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,032.07 | 2022-2024 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $587.35 | 2023-2025 | |
| Janssen Biotech, INC. | $453.29 | 2024-2025 | Tremfya, Simponi, Simponi Aria |
| Abbott Laboratories | $358.45 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $342.01 | 2022-2024 | |
| Lilly USA, LLC | $324.26 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Ucb, INC. | $267.39 | 2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $222.28 | 2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.19 | 2022-2024 | Jardiance, Spevigo |
| Sanofi-Aventis U.S. LLC | $177.06 | 2022-2024 | |
| Genzyme Corporation | $171.38 | 2025 | |
| Stryker Corporation | $142.86 | 2023 | Mako |
| Dexcom, INC. | $137.36 | 2022-2024 | Dexcom G6 Transmitter |
| Galderma Laboratories, L.P. | $125.00 | 2025 | Nemluvio |
| Bayer Healthcare Pharmaceuticals INC. | $77.88 | 2022-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $70.00 | 2023 | Korlym |
| Biofrontera INC. | $64.63 | 2024-2025 | Ameluz, Rhodoled Xl, Xepi |
| Amgen INC. | $55.13 | 2022-2023 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $54.89 | 2024 | Trelegy Ellipta |
| Organon LLC | $51.59 | 2025 | |
| Exact Sciences Corporation | $42.67 | 2023-2024 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $39.85 | 2022-2025 | Myosure Tissue Removal Device |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.56 | 2024 | Xifaxan |
| Mayne Pharma Commercial LLC | $34.21 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $33.26 | 2024 | Farxiga |
| Idorsia Pharmaceuticals US INC | $28.26 | 2023 | Quviviq |
| Sun Pharmaceutical Industries INC. | $27.47 | 2025 | |
| Cipher Pharmaceuticals US LLC | $26.55 | 2025 | Natroba, Spinosad |
| Novartis Pharmaceuticals Corporation | $21.58 | 2025 | |
| Shield Therapeutics INC | $19.29 | 2023 | Accrufer |
| Lucid Diagnostics INC. | $16.15 | 2023 | |
| Nevro Corp. | $14.85 | 2023 | Senza |
| Currax Pharmaceuticals LLC | $14.77 | 2024 | Contrave |
| Kerecis Limited | $13.14 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Biringer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.